Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VTYX - Ventyx Biosciences, Inc.
Market Cap 2.15B P/E - EPS this Y 19.10% Ern Qtrly Grth -
Income -192.96M Forward P/E -11.46 EPS next Y 3.00% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 6.00%
Dividend N/A Price/Book 5.76 EPS next 5Y - 52W High Chg -22.00%
Recommedations 2.20 Quick Ratio 11.33 Shares Outstanding 70.50M 52W Low Chg 143.00%
Insider Own 3.20% ROA -40.06% Shares Float 41.20M Beta 0.27
Inst Own 88.53% ROE -64.56% Shares Shorted/Prior 9.22M/9.19M Price 36.68
Gross Margin - Profit Margin - Avg. Volume 725,169 Target Price 10.80
Oper. Margin - Earnings Date Mar 25 Volume 316,151 Change -1.37%
Healthcare | Biotechnology | United States
About Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Ventyx Biosciences, Inc. News
03/11/24 Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
03/07/24 NodThera says inflammation drug has positive effect in Parkinson’s
03/07/24 Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
03/06/24 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
03/04/24 Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
02/27/24 Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
02/22/24 Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
02/06/24 Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/28/24 Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?
12/23/23 Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares
11/21/23 Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
11/10/23 Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference
11/09/23 Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
11/09/23 Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround
11/07/23 Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop
11/07/23 Ventyx revises TYK2 drug plans after lackluster study data
11/06/23 Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update
11/04/23 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
10/11/23 Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
10/10/23 Why Shares of Ventyx Biosciences Are Dropping Tuesday
VTYX Chatroom

User Image LabPsycho Posted - 4 days ago

See my post below: $VTYX I think this could retrace back down to the mid to upper $3's. Even at that price many are still up 50% in less than ~6 months.

User Image BobBuran Posted - 5 days ago

Friday Dow closes +211 and we close -$9,815 with $CETY $VTYX and $NUVB #stocks

User Image F4651110 Posted - 5 days ago

$VTYX smart money realising the news provided by another private company using NLRP3 method. This is major news for $VTYX and its obesity drug trials. The difference in NLRP3 is that its effect works sustainably even after dosage unlike $VKTX $LLY

User Image SocioCobb Posted - 5 days ago

$VTYX 3.04-3.97 gap -note to self

User Image LabPsycho Posted - 1 week ago

$VTYX I think this could retrace back down to the mid to upper $3's. Even at that price many are still up 50% in less than ~6 months.

User Image DG20 Posted - 1 week ago

$VTYX $ALT $TERN $TERN https://www.morningstar.com/news/marketwatch/20240416772/big-pharma-is-looking-to-fatten-profits-with-buyouts-of-weight-loss-drug-companies-here-are-4-candidates

User Image Capitulation_0 Posted - 1 week ago

$VTYX And this is de-risked in aficamten. It's going to get approved. It's the right timing for BP to get their sales force ready for the launch in < 1 year.

User Image Capitulation_0 Posted - 1 week ago

$VTYX Camzyos sales are projected at 4B+ based on BMY projections. Likely will achieved in 4-5 years.. so if you think aficamten will match camzyos revenue in 5 years.. that leaves ~13+ years ( patent ) for 4B sales, which roughly comes to ~52B for the life of the drug. Even at conservative estimate, it should be around ~40B. and Patent can be extended.

User Image Capitulation_0 Posted - 1 week ago

$VTYX seemed to have bottomed..

User Image Noobnioo Posted - 1 week ago

$RIOT ADPT stock will be a bull. It's cheap now. 15% profit. $SPY $QQQ $VTYX $FATE 🍀

User Image BugHunti Posted - 1 week ago

$VTYX

User Image BugHunti Posted - 1 week ago

$VTYX next profit here $arqt

User Image BugHunti Posted - 1 week ago

$VTYX thats it, point of trend reverse. going back to $40

User Image gianpinco Posted - 1 week ago

$VTYX 56% down since I bought. What an investment......

User Image pumpandumpslut Posted - 1 week ago

$VTYX

User Image NancyTsai84 Posted - 1 week ago

$VTYX Hi @DonCorleone77, Could you elaborate a bit on your post? I see you check out a lot of stocks so I wonder if you actually read the prospectus of every single stock. But here's my take on the stock. 1) The selling stockholder completed their purchase of $VTYX stocks approximately one month ago, on March 11th, 2024. The actual issuance of shares and subsequent dilution occurred during that period. 2) The selling stockholder acquired their 11.7 million shares at a price of $8.95 each a month ago. While there are no guarantees, wouldn’t they be less inclined to sell their shares at the current price of $4.60? 3) On the same day, March 11th, 2024, and ever since, analysts with well-respected reputations and proven track records (earning them ratings of 4.5+ out of 5 stars) have consistently praised $VTYX and gave them a buy rating with high price targets. This includes two price target upgrades to $16 and $12. I grabbed some today 😉

User Image pumpandumpslut Posted - 1 week ago

$VTYX options secured. May pop a few more next week if she keeps heading down

User Image BigLineSwings Posted - 1 week ago

$VTYX wow - If you bought within the last 26 trading days you gotta be kinda pissed - just keeps going down ! 🥹

User Image pumpandumpslut Posted - 1 week ago

$VTYX probably a good time to reenter soon

User Image DonCorleone77 Posted - 2 weeks ago

$VTYX Ventyx Biosciences files to sell 11.17M shares of common stock for holders

User Image Joe_088 Posted - 2 weeks ago

$VTYX buy and hold

User Image gianpinco Posted - 2 weeks ago

$VTYX painful to watch

User Image Joe_088 Posted - 2 weeks ago

$VTYX bottom for the next news VTX3232

User Image Capitulation_0 Posted - 2 weeks ago

$VTYX after such good news early March.. this has sold off from 8s to 5s.. geez

User Image Joe_088 Posted - 2 weeks ago

$VTYX

User Image LabPsycho Posted - 2 weeks ago

$VTYX Yep...

User Image LabPsycho Posted - 2 weeks ago

$VTYX @nevermind88 still up over 100% for many in less than 6 months, lots of room to retrace, especially considering the dilution. Big dumps knocking this below $4.90 today suggests to me going lower, at least $5 or below by option expiration, then further drift down perhaps?

User Image Capitulation_0 Posted - 2 weeks ago

$VTYX finally bottomed?

User Image Joe_088 Posted - 2 weeks ago

$VTYX load more and hold for VTX3232 news

User Image BhaiTuRehvaDe Posted - 3 weeks ago

$VTYX shit show

Analyst Ratings
Canaccord Genuity Buy Mar 13, 24
Wells Fargo Overweight Mar 12, 24
Oppenheimer Outperform Mar 12, 24
Canaccord Genuity Buy Mar 11, 24
Oppenheimer Perform Feb 21, 24
Wells Fargo Equal-Weight Dec 19, 23
Stifel Hold Dec 18, 23
Evercore ISI Group In-Line Nov 10, 23
Morgan Stanley Equal-Weight Nov 7, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Nuss John Chief Scientific Off.. Chief Scientific Officer Dec 20 Sell 2.1179 17,628 37,334 262,118 12/21/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Dec 20 Sell 2.1179 5,293 11,210 282,119 12/21/23
Mohan Raju CEO and President CEO and President Dec 20 Sell 2.1179 58,860 124,660 1,570,719 12/21/23
Mohan Raju CEO and President CEO and President Dec 17 Option 0.00 116,668 1,629,579 12/19/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Dec 17 Option 0.00 34,931 279,746 12/19/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Dec 17 Option 0.00 10,479 287,412 12/19/23
NSV Partners III LP 10% Owner 10% Owner Oct 09 Sell 30.0264 49,152 1,475,858 8,439,635 10/11/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Oct 05 Sell 29.11 30,000 873,300 1,512,911 10/06/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Oct 05 Option 8.04 30,000 241,200 1,542,911 10/06/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Oct 03 Sell 30.31 15,000 454,650 276,548 10/04/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Oct 03 Option 8.04 15,000 120,600 291,548 10/04/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Oct 03 Option 3.93 10,000 39,300 254,815 10/04/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Oct 03 Sell 30.33 10,000 303,300 244,815 10/04/23
Subramaniam Somu Director Director Sep 18 Sell 37.8123 56,665 2,142,634 8,488,787 09/20/23
NSV Partners III LP 10% Owner 10% Owner Sep 18 Sell 37.8123 56,665 2,142,634 8,488,787 09/20/23
Sandborn William J. See Remarks See Remarks Aug 31 Sell 33.64 11,900 400,316 48,389 09/01/23
Sandborn William J. See Remarks See Remarks Aug 31 Option 14.85 11,900 176,715 60,289 09/01/23
Sandborn William J. See Remarks See Remarks Aug 08 Sell 32.9 3,494 114,953 24,194 08/08/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Aug 07 Sell 34.1 30,000 1,023,000 1,512,911 08/08/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Aug 07 Option 8.04 30,000 241,200 1,542,911 08/08/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Aug 03 Sell 35.74 10,000 357,400 244,815 08/04/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Aug 03 Option 0.2 10,000 2,000 254,815 08/04/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Aug 03 Sell 35.73 15,000 535,950 276,548 08/04/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Aug 03 Option 8.04 15,000 120,600 291,548 08/04/23
Subramaniam Somu Director Director Jul 28 Sell 37.56 11,414 428,710 8,545,452 08/01/23
NSV Partners III LP 10% Owner 10% Owner Jul 28 Sell 37.56 11,414 428,710 8,545,452 08/01/23
Auster Martin Chief Financial Offi.. Chief Financial Officer Jul 25 Sell 35.54 28,000 995,120 47,649 07/26/23
Auster Martin Chief Financial Offi.. Chief Financial Officer Jul 25 Option 3.45 28,000 96,600 75,649 07/26/23
NSV Partners III LP Director Director Jul 07 Sell 35.91 100,000 3,591,000 9,552,965 07/19/23
Subramaniam Somu Director Director Jul 07 Sell 35.91 100,000 3,591,000 9,552,965 07/19/23
NSV Partners III LP Director Director Jul 11 Sell 37.58 31,921 1,199,591 8,556,866 07/13/23
Subramaniam Somu Director Director Jul 11 Sell 37.58 31,921 1,199,591 8,556,866 07/13/23
NSV Partners III LP 10% Owner 10% Owner Jul 03 Sell 37.74 134,080 5,060,179 9,652,965 07/06/23
Subramaniam Somu Director Director Jul 03 Sell 37.74 134,080 5,060,179 9,652,965 07/06/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Jul 05 Sell 39.14 30,000 1,174,200 1,512,911 07/05/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Jul 05 Option 8.04 29,785 239,471 1,542,911 07/05/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Jul 03 Sell 36.86 20,000 737,200 244,815 07/05/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Jul 03 Option 0.2 20,000 4,000 264,815 07/05/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Jul 03 Sell 36.75 15,000 551,250 276,548 07/05/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Jul 03 Option 4.12 15,000 61,800 291,548 07/05/23
Sandborn William J. See Remarks See Remarks Jul 03 Sell 40 15,387 615,480 27,688 07/05/23
Sandborn William J. See Remarks See Remarks Jul 03 Option 14.85 11,900 176,715 60,289 07/05/23
Sandborn William J. See Remarks See Remarks Jun 23 Sell 32.47 10,790 350,351 48,389 06/27/23
Sandborn William J. See Remarks See Remarks Jun 23 Option 0.2 10,790 2,158 59,179 06/27/23
Sandborn William J. See Remarks See Remarks Jun 15 Sell 34.31 3,487 119,639 31,175 06/16/23
Subramaniam Somu Director Director Jun 14 Sell 35.0757 50,000 1,753,785 9,787,045 06/16/23
NSV Partners III LP 10% Owner 10% Owner Jun 14 Sell 35.0757 50,000 1,753,785 9,787,045 06/16/23
Subramaniam Somu Director Director Jun 06 Sell 35.53 40,000 1,421,200 9,837,045 06/08/23
NSV Partners III LP 10% Owner 10% Owner Jun 06 Sell 35.53 40,000 1,421,200 9,837,045 06/08/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Jun 05 Sell 34.46 10,000 344,600 244,815 06/07/23